drugset / Trial / NCT06515314
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.
Timeline
- Start
- 2024-10-17
- Primary completion
- 2026-08-10
- Completion
- 2027-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRYZ-T102 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |